Safety and Efficacy in Type 2 Diabetic Patients With Severe Chronic Renal Impairment, 5 mg BI 1356 (Linagliptin) vs. Placebo, Insulin Background Inclusive
This study has been completed.
Study NCT00800683
Information provided by Boehringer Ingelheim Pharmaceuticals
First Received on December 1, 2008.
Last Updated on February 13, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
